- Application of DSCSA and exemptions
- Understanding primary timelines for key stakeholders
- New investigation and reporting requirements for “suspect” and “illegitimate” products
- Methods for meeting January 1, 2015 deadlines
- Resources for further information
Speakers:
Chris Markus
Partner
King & Spalding
Elaine H. Tseng
Partner
King & Spalding
Caitlyn Ozier
Associate
King & Spalding
Contact:
Brooke Akins | Division Director, Life Science Programs
312.224.1693 | webinars@q1productions.com
CONTACT US
Q1 Productions
500 N. Dearborn Suite 500
Chicago, IL 60654
T: 312.822.8100
F: 312.873.3969
marketing@q1productions.com